Skip to main content
. 2014 Mar 18;171(7):1722–1734. doi: 10.1111/bph.12568

Figure 2.

Figure 2

Dose–response curves to Angeli's salt (AS) (n = 8) on coronary flow in the absence and presence of (A) the HNO scavenger L-cysteine (4 mM, n = 6), the NO scavenger HXC (100 μM, n = 5) or the reducing agent DTT (100 μM, n = 5); and (B) the sGC inhibitor ODQ (10 μM, n = 6), the CGRP receptor antagonist CGRP8–37 (0.1 μM, n = 5) and the Kv channel inhibitor 4-AP (1 mM, n = 5). Serial bolus doses of 10 mM NaOH vehicle are shown for comparison (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 versus AS; two-way anova with Bonferroni post hoc test for multiple comparisons. (C) The dose–response curves to DEA-NO (n = 5) on coronary flow in the absence and presence of HXC (100 μM, n = 5) are shown for comparison.